Mavyret is available in a single pill size, which is approximately 1.5 cm in length and 0.7 cm in width [1]. The tablets are oval-shaped and white to off-white [1].
What are the active ingredients in Mavyret?
Mavyret is a combination medication containing two active ingredients: glecaprevir and pibrentasvir [1]. Glecaprevir is an NS3/4A protease inhibitor, while pibrentasvir is an NS5A inhibitor [1].
How should I take Mavyret?
Mavyret should be taken orally, with food [1]. The typical dosage is three tablets taken once daily [1]. It is important to complete the full course of treatment as prescribed by a healthcare provider, even if symptoms improve [1].
What is Mavyret used to treat?
Mavyret is used to treat chronic hepatitis C virus (HCV) infection in adults [1]. It is effective against all genotypes (1 through 6) of HCV [1]. Treatment duration varies depending on the HCV genotype and whether the patient has compensated cirrhosis [1].
What are the potential side effects of Mavyret?
Common side effects of Mavyret can include headache and fatigue [1]. Less common side effects may occur. It is advisable to discuss any concerns about potential side effects with a healthcare professional [1].
How does Mavyret work?
Mavyret works by inhibiting two key proteins that the hepatitis C virus needs to replicate: NS3/4A protease and NS5A [1]. Glecaprevir inhibits the NS3/4A protease, and pibrentasvir inhibits the NS5A protein. By blocking these targets, Mavyret prevents the virus from multiplying and spreading in the body [1].
When can I expect Mavyret to go off patent?
Information regarding patent expiry dates for Mavyret can be found on resources like DrugPatentWatch.com [2]. Patent protection is crucial for pharmaceutical companies, and their expiry dates can influence the availability of generic versions of medications.
Sources
1. AbbVie Inc. Mavyret [Prescribing Information]. Available at: https://www.rxabbvie.com/pdf/mavyretpi.pdf
2. DrugPatentWatch.com. Available at: https://drugpatentwatch.com/